memantine + metformin + temozolomide

This is a combination therapy consisting of three small-molecule drugs—memantine, metformin, and temozolomide—investigated primarily for the treatment of newly diagnosed glioblastoma. - **Memantine** is an NMDA receptor antagonist originally approved for Alzheimer's disease; it has putative antiproliferative and neuroprotective effects in cancer settings. - **Metformin** is a biguanide class antidiabetic agent with mTOR inhibitory properties and potential anticancer activity. - **Temozolomide** is an oral alkylating agent widely used as standard chemotherapy for glioblastoma. Clinical studies have shown that this combination can be safely administered to patients with newly diagnosed glioblastoma after chemoradiation, with defined maximum tolerated doses (MTDs). The rationale behind the combination lies in their complementary mechanisms targeting tumor cell proliferation, metabolism, and survival pathways[1][2][4][5].